Apomorphine in the Treatment of Parkinson’s DiseaseSerhat Özkan1, Sevda Erer2, Bülent Elibol3, Sehür Sibel Özkaynak4, Raif Çakmur5, Muhittin Cenk Akbostancı6, Haşmet Hanağası7, Okan Doğu8 1Eskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, Turkey 2Uludag University Faculty of Medicine, Department of Neurology, Bursa, Turkey 3Hacettepe University Faculty of Medicine, Department of Neurology, Ankara, Turkey 4Akdeniz University Faculty of Medicine, Department of Neurology, Antalya, Turkey 5Dokuz Eylul University Faculty of Medicine, Department of Neurology, Izmir, Turkey 6Ankara University Faculty of Medicine, Department of Neurology, Ankara, Turkey 7Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey 8Mersin University Faculty of Medicine, Department of Neurology, Mersin, Turkey
Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson’s disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a “treatment management guideline,” which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature. Keywords: Apomorphine, Parkinson’s disease, treatment
Serhat Özkan, Sevda Erer, Bülent Elibol, Sehür Sibel Özkaynak, Raif Çakmur, Muhittin Cenk Akbostancı, Haşmet Hanağası, Okan Doğu. Apomorphine in the Treatment of Parkinson’s Disease. Turk J Neurol. 2021; 27(4): 358-365
Corresponding Author: Serhat Özkan, Türkiye |
|